Application note: Effect of perfluorinated alcohols in impurity analysis for synthetic oligonucleotides
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
List view / Grid view
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Silencing RNA, or siRNA, are short, double-stranded RNA molecules which are not only an important research tool in molecular biology, but also an emerging therapeutic modality.
Superficially porous particle technologies provide a reduced diffusion path in comparison with their fully porous counterparts minimising the resistance to mass transfer during chromatographic separation.
Researchers have sequenced SARS-CoV-2, revealing at least six strains with little variability, useful information for vaccine developers.
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
The third phase of the ENCODE project has been released, with new information on genes and their potential regulators in their respective genomes.
A new technology named OligoFISSEQ has been created which can image and three-dimensionally map the genomes in hundreds of cells at the same time.
Researchers have created a new method of potentially treating herpes virus, by targeting the physical properties of the viral genome.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
A new CRISPR technology has been created to understand mutations based on cytosine to guanine base changes and minimise unintended "off-target" mutations.
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
A new study reveals that the Toxoplasma gondii parasite acts through the IRE1 protein to cause infected cells to migrate through the body, spreading the parasite.
Researchers reveal a combination of PD1 immunotherapy and BMI1 protein inhibition eliminated cancer stem cells and prevented cancer recurrence in a mouse model.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.